The meeting came as divisions grow in Europe over the proposed tariffs
auto4 hours ago
Five key genes are linked with the most severe form of Covid-19, scientists said on Friday, in research that also pointed to several existing drugs that could be repurposed to treat people who risk getting critically ill with the pandemic disease.
Researchers who studied the DNA of 2,700 Covid-19 patients in 208 intensive care units across Britain found that five genes involving in two molecular processes - antiviral immunity and lung inflammation - were central to many severe cases.
"Our results immediately highlight which drugs should be at the top of the list for clinical testing," said Kenneth Baillie, an academic consultant in critical care medicine at Edinburgh University who co-led the research.
The genes - called IFNAR2, TYK2, OAS1, DPP9 and CCR2 – partially explain why some people become desperately sick with Covid-19, while others are not affected, Baillie said.
The findings, published in the journal Nature, should help scientists speed up the search for potential drugs for Covid-19 by conducting clinical trials of medicines that target specific antiviral and anti-inflammatory pathways.
Among those with the most potential, he said, should be a class of anti-inflammatory drugs called JAK inhibitors, which includes the arthritis drug baricitinib, made by Eli Lilly .
Baillie's team also found that a boost in the activity of the INFAR2 gene is could create protection against Covid-19, because it is likely to mimic the effect of treatment with interferon.
Various existing drugs are being explored in clinical trials for their potential against Covid-19 including interferon-beta-1a, interleukin-1 receptor antagonist and Sanofi's arthritis drug Kevzara.
So far, a steroid called dexamethasone and a newly developed antiviral called remdesivir, made by Gilead, are the only drugs authorised around the world to treat Covid-19 patients - although remdesivir is not recommended for severe cases of the disease and has had mixed results in trials.
Last month, the US Food and Drug Administration approved Eli Lilly's antibody drug for Covid-19, bamlanivimab, for patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
Sir Mark Caulfield, chief scientist for Genomics England and director of the NIHR Biomedical Research Centre at Barts Hospital, called Friday's research "a remarkable result".
He said the team's study of patient genomes could eventually create a "comprehensive inventory of variants that change our susceptibility to the severity of Covid".
"And maybe, just maybe, as a result we will find a new therapy that will help people survive this better."
The meeting came as divisions grow in Europe over the proposed tariffs
auto4 hours ago
Around 44% of total financing had a climate financing component
finance4 hours ago
World Cup-winning coach Dav Whatmore asked the young boy to watch YouTube videos of his favourite batsman
cricket4 hours ago
Flare-up in Middle East tensions also supporting oil
energy4 hours ago
Weekly jobless claims fall 12,000 to 219,000
economy5 hours ago
Volkswagen said this month it needed to cut costs significantly
auto5 hours ago
Many told the war revived traumas of past conflicts with some suffering panic attacks after hearing Israeli sonic booms or other loud bangs
mena5 hours ago
Dubai’s real estate market continues to be a global hotspot
realty5 hours ago